Moreover, CRISPR-Cas9-mediated BATF knock-out in activated Tregs informed that BATF was vital in the stimulation and survival of activated Tregs, suggesting a potential opportunity to therapeutically target tumour-associated Tregs without affecting immune homeostasis [165]. The gene discussed is BATF; the disease is neoplasm.